浩欧博与罗氏诊断合作推进，前三季度营收净利双降

Business Developments - In October 2025, the company signed a cooperation framework agreement with Roche Diagnostics to collaborate in the field of chemiluminescent self-antibody detection products [1] - In December 2025, the company's wholly-owned subsidiary obtained a medical device registration certificate for the "Immunoglobulin G4 (IgG4) Testing Kit" [1] - In January 2026, the company's "Nabok" chemiluminescent platform received a medical device registration certificate for new mixed allergen screening and ragweed detection projects, indicating ongoing R&D and market expansion in the in vitro diagnostics sector [1] Financial Performance - For the first nine months of 2025, the company reported revenue of 292 million yuan, a year-on-year decrease of 4.84% [2] - The net profit attributable to the parent company was 26.19 million yuan, down 1.41% year-on-year [2] - The gross profit margin stood at 59.17%, with a debt ratio of 14.11% [2] Stock Performance - As of February 10, 2026, the company's stock price was 145.25 yuan per share, reflecting a year-to-date decline of 5.56% and a 20-day decline of 7.66% [3] - On that day, the net outflow of main capital was 1.9648 million yuan, with a turnover rate of 0.56% [3] - No specific future events have been disclosed for February 14, 2026, or beyond, regarding financial report dates or shareholder meetings, with regular announcements to be made by the company [3]